cilofexor   Click here for help

GtoPdb Ligand ID: 10644

Synonyms: example 13/9 [US10485795B2] | GS-9674 | GS9674
PDB Ligand
Compound class: Synthetic organic
Comment: Cilofexor (GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist. It was originally identified by Phenex Pharmaceuticals [1] and is being developed by Gilead Pharmaceuticals for hepatic anti-steatotic activity, and potential to treat nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH). Successful treatment of these liver conditions will most likely be achieved using combinations of antilipemic, anti-inflammatory and anti-fibrotic agents.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 108.92
Molecular weight 585.06
XLogP 6.49
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OC(=O)c1ccnc(c1)N1CC(C1)(O)c1ccc(cc1Cl)OCc1c(onc1c1c(Cl)cccc1Cl)C1CC1
Isomeric SMILES OC(=O)c1ccnc(c1)N1CC(C1)(O)c1ccc(cc1Cl)OCc1c(onc1c1c(Cl)cccc1Cl)C1CC1
InChI InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)
No information available.
Summary of Clinical Use Click here for help
Cilofexor (GS-9674) has progressed to Phase 3 evaluation in patients with primary sclerosing cholangitis. Phase 2 results in this indication were published in 2019 [3]. Click here to link to's full list of GS-9674 studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02781584 Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2 Interventional Gilead Sciences
NCT03890120 Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis Phase 3 Interventional Gilead Sciences